- Sierra preparing to launch the MOMENTUM Phase 3 myelofibrosis clinical trial expected in Q4 2019 - - Exploring non-dilutive options to support future continued development of DDR portfolio -...
Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and...
- Corporate prioritization of portfolio to focus resources on advancement of momelotinib - - Exploring non-dilutive options to support future continued development of SRA737 and SRA141 -...
View all news releases
Targeted Therapeutics for Hematology & Oncology – Q3 2019
View All Presentations
View all events and webcasts
James Smith, Vice President Corporate Affairs
Sign up for investor alerts